Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract InfectionsChintan V. Dave, Elisabetta Patorno, Sebastian Schneeweiß et al.|Annals of Internal Medicine|2019Cited by 215
Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA TherapyChintan V. Dave, Elisabetta Patorno, Angela Tong et al.|Circulation|2020Cited by 93
Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United StatesJohn W. Ostrominski, Elisabetta Patorno, Deborah J. Wexler et al.|Annals of Internal Medicine|2025Cited by 18